China Fosun's sale of Gland Pharma could be India's biggest pharma dea (2024)

FAQs

China Fosun's sale of Gland Pharma could be India's biggest pharma dea? ›

If the deal goes forward, it will be India's biggest pharma deal, a report by the Economic Times (ET) said. Currently, Fosun owns a 57.86 per cent stake in the Indian generic injectable maker Gland Pharma. Fosun acquired Gland Pharma in 2017 for $1.1 billion. It was listed in 2020 in a Rs 6,480 crore IPO.

BENGALURU (Reuters) - China's Shanghai Fosun Pharmaceutical Group Co Ltd has withdrawn plans to sell stake in Indian drugmaker Gland Pharma Ltd, ET Now tweeted on Wednesday, citing sources. Fosun Pharma holds a 57.86% stake in the Indian company.

Gland Pharma Limited IPO (Gland Pharma IPO) Detail. Gland Pharma IPO is a book built issue of Rs 6,479.55 crores. The issue is a combination of fresh issue of 0.83 crore shares aggregating to Rs 1,250.00 crores and offer for sale of 3.49 crore shares aggregating to Rs 5,229.55 crores.

6499 Cr. was raised in the Gland Pharma IPO of 43,196,968 equity shares with a face value of ₹1. The issue was priced at ₹1490 to ₹1500 per share and the initial public offering (IPO) took place between November 9 and November 11, 2020. Friday, November 20, 2020 saw the company's stock listing on the exchanges.

Gland Pharma's therapeutic categories include anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, fertility supplements and antagonists, among others. Its facilities are located in Hyderabad and Visakhapatnam, India.

There are 13 analysts who have initiated coverage on Gland Pharma. There are 5 analysts who have given it a strong buy rating & 3 analysts have given it a buy rating.

Shares of Gland Pharma Ltd. fell nearly 7% on Tuesday to its lowest level in over two weeks. The drop came after 9.3 million shares, or 5.66% stake of the company, changed hands in a large trade. The trade happened at Rs 1,743.95 apiece, according to data from Cogencis.

Gland Pharma Share Price in 2030 is predicted to remain between Rs 6,680 and Rs 3,532. What is the Gland Pharma Share Price Target 2027? Gland Pharma Share Price Target 2027 is between Rs 4,255 and Rs 2,651.

India Ratings and Research (Ind-Ra) has upgraded Gland Pharma Limited's (GPL) Long-Term Issuer Rating to 'IND AA-' from 'IND A+'.

Who owns Gland Pharma? ›

Company is virtually debt free. Company has a healthy Interest coverage ratio of 142.41. The Company has been maintaining an effective average operating margins of. Company has a healthy liquidity position with current ratio of 9.43.

Srinivas Sadu is the MD and CEO of our Company. He holds master's degree in Industrial Pharmacy from Long Island University, New York; MBA from University of Maryland, Baltimore; and postgraduate certification in Finance and Management from London School of Business and Finance.

Johnson & Johnson is the leading Pharma company by market cap in the US (as of Mar 31, 2023).

Gland Pharma employs 1,001 to 5,000 employees in India.

In financial year 2023, Gland pharma Limited's revenue from operation was valued at over 36 billion Indian rupees. This Indian company was acquired by Fosun Pharmaceuticals, a Chinese listed pharmaceutical company in 2016.

Lakumi Trust and Nicomac Machinery Pvt Ltd disposed of 81.20 lakh shares of Gland Pharma in separate bulk deals on the National Stock Exchange (NSE) China's Fosun Pharma is the promoter of Gland Pharma and holds a 57.86 per cent stake in the firm.

Fosun International grew by taking over a good number of companies and presides over real estate and steel companies, Greek jewelry brand Folli Follie, French resort operator Club Med and an insurance company that used to be a group firm of Portuguese saving bank Caixa Geral de Depositos.

Shares of Gland Pharma Ltd plunged as much as 6.7% in trade on Tuesday, April 9, after a huge block deal was executed on the stock counter. Almost 90.8 lakh shares of Gland Pharma, forming 5.5% of the company's equity, changed hands in a block deal worth ₹1,590 crore.

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for Plerixafor Injection, 24 mg/1.2 mL (20 mg/mL), Single-Dose Vial (Product).